Immune Intervention in Sepsis
- PMID: 34335278
- PMCID: PMC8317843
- DOI: 10.3389/fphar.2021.718089
Immune Intervention in Sepsis
Abstract
Sepsis is a host immune disorder induced by infection. It can lead to multiple organ dysfunction syndrome (MODS), which has high morbidity and mortality. There has been great progress in the clinical diagnosis and treatment of sepsis, such as improvements in pathogen detection technology, innovations regarding anti-infection drugs, and the development of organ function support. Abnormal immune responses triggered by pathogens, ranging from excessive inflammation to immunosuppression, are recognized to be an important cause of the high mortality rate. However, no drugs have been approved specifically for treating sepsis. Here, we review the recent research progress on immune responses in sepsis to provide a theoretical basis for the treatment of sepsis. Constructing and optimizing a dynamic immune system treatment regimen based on anti-infection treatment, fluid replacement, organ function support, and timely use of immunomodulatory interventions may improve the prognosis of sepsis patients.
Keywords: cytokine; immune intervention; immunosuppression; inflammatory; sepsis.
Copyright © 2021 Chen and Wei.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
The Critical Roles and Mechanisms of Immune Cell Death in Sepsis.Front Immunol. 2020 Aug 25;11:1918. doi: 10.3389/fimmu.2020.01918. eCollection 2020. Front Immunol. 2020. PMID: 32983116 Free PMC article. Review.
-
Immune dysregulation in sepsis: experiences, lessons and perspectives.Cell Death Discov. 2023 Dec 19;9(1):465. doi: 10.1038/s41420-023-01766-7. Cell Death Discov. 2023. PMID: 38114466 Free PMC article. Review.
-
[Research progress on the organ-protective effect of Maresin-1 in sepsis].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024 Feb;36(2):211-215. doi: 10.3760/cma.j.cn121430-20230718-00522. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 38442942 Review. Chinese.
-
Review of research progress on the role of the effective components of traditional Chinese medicine in sepsis with multiple organ dysfunction.Heliyon. 2023 Oct 28;9(11):e21713. doi: 10.1016/j.heliyon.2023.e21713. eCollection 2023 Nov. Heliyon. 2023. PMID: 38027612 Free PMC article. Review.
-
[Consensus of Chinese experts on early prevention and blocking of sepsis].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 May;32(5):518-530. doi: 10.3760/cma.j.cn121430-20200514-00414. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32576341 Chinese.
Cited by
-
Septic macrophages induce T cells immunosuppression in a cell-cell contact manner with the involvement of CR3.Heliyon. 2023 Dec 3;10(1):e23266. doi: 10.1016/j.heliyon.2023.e23266. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187232 Free PMC article.
-
Bacterial lipopolysaccharide-induced endothelial activation and dysfunction: a new predictive and therapeutic paradigm for sepsis.Eur J Med Res. 2023 Sep 12;28(1):339. doi: 10.1186/s40001-023-01301-5. Eur J Med Res. 2023. PMID: 37700349 Free PMC article. Review.
-
Hypericum sampsonii exhibits anti-inflammatory activity in a lipopolysaccharide-induced sepsis mouse model.J Tradit Complement Med. 2023 Mar 2;13(4):379-388. doi: 10.1016/j.jtcme.2023.03.002. eCollection 2023 Jul. J Tradit Complement Med. 2023. PMID: 37396154 Free PMC article.
-
To Determine the Genotyping of Fc-gamma Receptor FCGR2A Polymorphism as Genetic Susceptibility to Neonatal Sepsis: A Study from a Tertiary Center of North India.J Indian Assoc Pediatr Surg. 2022 Nov-Dec;27(6):718-722. doi: 10.4103/jiaps.jiaps_52_22. Epub 2022 Nov 14. J Indian Assoc Pediatr Surg. 2022. PMID: 36714470 Free PMC article.
-
Editorial: Cell signaling status alteration in development and disease.Front Cell Dev Biol. 2022 Dec 1;10:1068887. doi: 10.3389/fcell.2022.1068887. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36531965 Free PMC article. No abstract available.
References
-
- Abraham E., Glauser M. P., Butler T., Garbino J., Gelmont D., Laterre P. F., et al. (1997). p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients with Severe Sepsis and Septic Shock. JAMA 277, 1531–1538. 10.1001/jama.277.19.153110.1001/jama.1997.03540430043031 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
